Related Experiment Video
Updated: Jul 25, 2025

Covalent Binding of BMP-2 on Surfaces Using a Self-assembled Monolayer Approach
Published on: August 26, 2013
Moderate-Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein-2
Jonathan Dorogin1, Henry B Hochstatter1,2, Samantha O Shepherd3
1Department of Bioengineering, Knight Campus for Accelerating Scientific Impact, University of Oregon, 6231 University of Oregon, Eugene, OR, 97403, USA.
Researchers developed novel affibodies to control bone morphogenetic protein-2 (BMP-2) release. These protein binders, when conjugated to hydrogels, effectively modulate BMP-2 delivery and activity for potential clinical use.
Area of Science:
- Biomaterials Science
- Protein Engineering
- Regenerative Medicine
Background:
- Uncontrolled release of bone morphogenetic protein-2 (BMP-2) can cause adverse effects, necessitating controlled delivery systems.
- Affibodies, engineered protein binders, offer a potential solution for targeted BMP-2 modulation.
- Understanding BMP-2 binding kinetics and mechanisms is crucial for therapeutic applications.
Purpose of the Study:
- To identify and characterize BMP-2-specific affibodies with varying affinities.
- To investigate the binding interactions between affibodies and BMP-2 using biophysical methods.
- To evaluate the efficacy of affibody-conjugated hydrogels in controlling BMP-2 release and biological activity.
Main Methods:
- Yeast surface display for affibody library screening.
- Biolayer interferometry to determine binding kinetics (KD, koff).
- Computational modeling to predict binding sites.
- In vitro studies using C2C12 myoblasts to assess alkaline phosphatase (ALP) activity.
- Fabrication and evaluation of affibody-conjugated hydrogels for BMP-2 release.
Main Results:
- High- and low-affinity affibodies targeting distinct BMP-2 sites were identified.
- Affibody binding reduced BMP-2-induced alkaline phosphatase (ALP) expression in myoblasts.
- Affibody-conjugated hydrogels enhanced BMP-2 uptake and controlled its release over four weeks.
- High-affinity hydrogels demonstrated significantly lower BMP-2 release compared to low-affinity and affibody-free hydrogels.
- BMP-2 loaded into hydrogels prolonged myoblast ALP activity.
Conclusions:
- Affibodies can be engineered to modulate BMP-2 binding affinity and delivery kinetics.
- Affibody-conjugated hydrogels provide a promising platform for controlled BMP-2 release.
- This approach offers potential for improved therapeutic outcomes in bone regeneration and other clinical applications.
- The differential binding and release characteristics highlight the tunable nature of this system.
More Related Videos
11:20Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
11:38Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
Related Concept Videos
TGF - β Signaling Pathway
Affinity and Avidity
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...